Navigation Links
Cumberland Pharmaceuticals Reports 2011 Annual Financial Results
Date:2/29/2012

NASHVILLE, Tenn., Feb. 29, 2012 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced 2011 annual financial results.

Net Revenue:  For the year ended December 31, 2011, net revenue increased to $51.1 million, up 11.5% compared with $45.9 million for 2010.

For the three months ended December 31, 2011, net revenue was $13.0 million, up from $12.8 million in the prior year period.

Operating Expenses:  For the year ended December 31, 2011, total operating expenses were approximately $41.3 million, compared with $39.4 million for 2010. The difference was primarily a result of increased cost of products sold, research and development and general and administrative expenses, partially offset by lower selling and marketing expenses.

Total operating expenses for the three months ended December 31, 2011 were $11.3 million compared to $10.6 million the prior year period. Increases in cost of products sold, research and development expenses and general and administrative expenses were partially offset by a decrease in selling and marketing expenses compared to the prior year.  

Net Income:  Net income attributable to common shareholders for the year ended December 31, 2011 increased more than 130% to $5.7 million, or $0.28 per diluted share, compared to $2.5 million, or $0.12 per diluted share, for 2010.

Net income attributable to common shareholders for the three months ended December 31, 2011, was $0.9 million, or $0.04 per diluted share, similar to the same period in 2010.

Balance Sheet:  As of December 31, 2011, Cumberland had $70.6 million in cash and cash equivalents, compared to $65.9 million at the end of 2010. Total assets at December 31, 2011, were $95.5 million co
'/>"/>

SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Cumberland Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 10, 2009
2. Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
3. Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort
4. Cumberland Pharmaceuticals Reports 24% Increase in Net Revenue With Full Year 2009 Financial Results
5. Cumberland Pharmaceuticals Partners in Canada With Alveda Pharmaceuticals to Commercialize Caldolor(R)
6. Cumberland Pharmaceuticals To Announce First Quarter 2010 Financial Results on May 13, 2010
7. Cumberland Pharmaceuticals to Present at Jefferies Global Life Sciences Conference in New York on June 8, 2010
8. Cumberland Pharmaceuticals to Present at the Wells Fargo Healthcare Conference in Boston on June 23, 2010
9. Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results
10. Cumberland Pharmaceuticals Announces Extension of FDA Review of Acetadote® Supplemental New Drug Application
11. Cumberland Pharmaceuticals and Phebra Pty Ltd. Announce the Launch of Acetadote® in Australia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... PASADENA, Calif. , March 26, 2015 ... San Gabriel Valley to perform transcatheter aortic valve replacement ... TAVR procedure is a revolutionary new way to replace ... use of a heart lung machine. The ... heart team led by Azhil ( Alex) Durairaj , ...
(Date:3/26/2015)... VANCOUVER, British Columbia, March 26, 2015  OncoGenex ... a summary of clinical developments and announced fourth ... Clinical Developments and Anticipated Near-term MilestonesCustirsen ... and Teva agreed to negotiate the termination of ... Negotiations of the final termination agreement are ongoing. ...
(Date:3/26/2015)... March 26, 2015 According to ... Procedure Volume, Technology (RF, Microwave, Cryoablation, Others), Department (Interventional ... Cancer, Bone Metastasis) - Global Forecasts to 2019", published ... reach around $462.0 Million growing at a CAGR of ... tables and 57 figures spread through 195 pages and ...
Breaking Medicine Technology:Huntington Memorial Hospital Performs Groundbreaking Minimally Invasive Replacement of Heart Valves 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 3OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 4OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 5OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 6OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 7OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 8Tumor Ablation Market Worth $462.0 Million by 2019 2Tumor Ablation Market Worth $462.0 Million by 2019 3Tumor Ablation Market Worth $462.0 Million by 2019 4
... 2011 Cardica, Inc. (Nasdaq: CRDC ) today ... 30, 2011. Cardica,s management will host a conference call at ... and provide an update on the company,s business. ... Dr. Swanstrom, a world-renowned key opinion leader in laparoscopic surgery, ...
... ($ in millions, except per share data, unaudited)ItemQ3 2011Q3 ... Net Product Revenue , $112.9 , 16.9% increaseNaglazyme Net ... Product Revenue* , $23.0 , $16.5Kuvan Net Product ... , $3.5 , 59.1% increaseGAAP Net Income (Loss) , ...
Cached Medicine Technology:Cardica Announces Fiscal 2012 First Quarter Financial Results 2Cardica Announces Fiscal 2012 First Quarter Financial Results 3Cardica Announces Fiscal 2012 First Quarter Financial Results 4Cardica Announces Fiscal 2012 First Quarter Financial Results 5Cardica Announces Fiscal 2012 First Quarter Financial Results 6BioMarin Announces Third Quarter 2011 Financial Results 2BioMarin Announces Third Quarter 2011 Financial Results 3BioMarin Announces Third Quarter 2011 Financial Results 4BioMarin Announces Third Quarter 2011 Financial Results 5BioMarin Announces Third Quarter 2011 Financial Results 6BioMarin Announces Third Quarter 2011 Financial Results 7BioMarin Announces Third Quarter 2011 Financial Results 8BioMarin Announces Third Quarter 2011 Financial Results 9BioMarin Announces Third Quarter 2011 Financial Results 10BioMarin Announces Third Quarter 2011 Financial Results 11BioMarin Announces Third Quarter 2011 Financial Results 12BioMarin Announces Third Quarter 2011 Financial Results 13
(Date:3/27/2015)... (PRWEB) March 27, 2015 The federal ... that allege the statin medication increases the risk that ... Pfizer Inc.’s Motion to Dismiss four individual cases that ... Case Management Order issued in the U.S. District Court, ... determined that the dismissals were warranted because the plaintiffs ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 Bleeding ... patients undergoing percutaneous coronary intervention (PCI), resulting in ... observed a “risk-treatment paradox,” in which the highest-risk ... treatment are treated less often with bleeding avoidance ... Saint Luke’s Mid America Heart Institute asked the ...
(Date:3/27/2015)... Healthpointe is proud to announce that ... now treating knee and hip joint disorders in practice ... Beach, and La Mirada. Dr. Stanley Katz specializes in ... joint disorders as well as chronic conditions such as ... his patients back to their normal lives. Many ...
(Date:3/27/2015)... New York, NY (PRWEB) March 27, 2015 Ticket ... Live in Concert in 2015. After a phenomenal and ... hit show "Nashville" will be going out on tour again in ... The tour gets underway on April 29th in New York ... Phoenix, AZ at the Comerica Theatre on May 10th. , Fans ...
(Date:3/27/2015)... While deep learning was the topic of ... (GTC) , the CEO of one start-up spoke passionately about ... lifespan well beyond the generally-agreed ceiling of 120 years. , ... one of 12 companies recognized as the hottest GPU-powered startups ... GTC Emerging Companies Summit have business models focused ...
Breaking Medicine News(10 mins):Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 2Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 3Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 2Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 3Health News:Fellowship-Trained and Board-Certified Orthopedic Surgeon is Now Treating Knee and Hip Joint Disorders in Anaheim, California 2Health News:Fellowship-Trained and Board-Certified Orthopedic Surgeon is Now Treating Knee and Hip Joint Disorders in Anaheim, California 3Health News:Nashville Live in Concert Tickets in New York, Boston, Washington, DC, Chicago, Minneapolis, San Francisco, Los Angeles and Phoenix Now On Sale at TicketDown.com 2Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 2Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 3
... ORLANDO, Fla. Results of a study presented at the ... credence to the idea that improving quality of life affects ... cancer. Researchers know that telomeres shorten and deteriorate with ... length. "We are trying to understand the interconnections between ...
... , FRIDAY, April 1 (HealthDay News) -- At-home pregnancy tests ... on the way and if it is time to call ... offer tantalizing clues about future health risks -- are still ... results may puzzle or even panic consumers who don,t seek ...
... use has been linked to thicker arteries, possibly contributing to ... of twin veterans. The data is being presented Tuesday, April ... Orleans. Depression can heighten the risk for heart disease, ... is separate and independent from depression itself, says first author ...
... Germany, Saturday 02 April 2011: Exciting new data presented ... quadruple therapy in chronic hepatitis C (HCV) patients suppressed ... 100% rate of sustained virological response - undetectable HCV ... the quadruple therapy study, HCV patients were given four ...
... Fla. The combination of two compounds that inhibit ... showing promise in an ongoing Phase I trial, according ... 2011, held here April 2-6. The research, ... GDC-0973, which inhibits MEK1/2 and GDC-0941, which inhibits PI3K. ...
... (HealthDay News) -- Updated guidelines to keep children happy, safe ... week by the American Academy of Pediatrics. When deciding ... and overall well-being, to ensure their child can effectively participate ... and mentally prepare their child for camp, and team with ...
Cached Medicine News:Health News:Chronic stress of cancer causes accelerated telomere shortening 2Health News:Do At-Home Genetic Tests Tell Too Much and Explain Too Little? 2Health News:Do At-Home Genetic Tests Tell Too Much and Explain Too Little? 3Health News:Antidepressants linked to thicker arteries 2Health News:Quadruple therapy shows 100 percent SVR for HCV patients previously unresponsive to treatment 2Health News:Combining MEK and PI3K inhibitors appears encouraging in a safety study with early signs of anti-tumor activity 2Health News:Pediatrics Group Offers Guidelines to Keep Young Campers Safe, Healthy 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: